ORMP
Price
$3.31
Change
-$0.11 (-3.22%)
Updated
Feb 5, 03:30 PM (EDT)
Capitalization
136.12M
20 days until earnings call
Intraday BUY SELL Signals
PMN
Price
$14.00
Change
-$1.65 (-10.54%)
Updated
Feb 5, 03:36 PM (EDT)
Capitalization
34.44M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORMP vs PMN

Header iconORMP vs PMN Comparison
Open Charts ORMP vs PMNBanner chart's image
Oramed Pharmaceuticals
Price$3.31
Change-$0.11 (-3.22%)
Volume$100
Capitalization136.12M
Promis Neurosciences
Price$14.00
Change-$1.65 (-10.54%)
Volume$100
Capitalization34.44M
ORMP vs PMN Comparison Chart in %
ORMP
Daily Signal:
Gain/Loss:
PMN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ORMP vs. PMN commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and PMN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ORMP: $3.42 vs. PMN: $15.65)
Brand notoriety: ORMP and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 88% vs. PMN: 23%
Market capitalization -- ORMP: $136.12M vs. PMN: $34.44M
ORMP [@Biotechnology] is valued at $136.12M. PMN’s [@Biotechnology] market capitalization is $34.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 2 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • ORMP’s FA Score: 2 green, 3 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 2 TA indicator(s) are bullish while PMN’s TA Score has 6 bullish TA indicator(s).

  • ORMP’s TA Score: 2 bullish, 6 bearish.
  • PMN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PMN is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а -1.44% price change this week, while PMN (@Biotechnology) price change was +29.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ORMP is expected to report earnings on Feb 25, 2026.

PMN is expected to report earnings on Apr 06, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($136M) has a higher market cap than PMN($34.4M). PMN has higher P/E ratio than ORMP: PMN (7.78) vs ORMP (3.42). PMN YTD gains are higher at: 129.304 vs. ORMP (28.721). ORMP has higher annual earnings (EBITDA): 55.9M vs. PMN (-29.28M). ORMP (15.8M) and PMN (15.4M) have equal amount of cash in the bank . ORMP has less debt than PMN: ORMP (860K) vs PMN (4.05M). ORMP has higher revenues than PMN: ORMP (2M) vs PMN (0).
ORMPPMNORMP / PMN
Capitalization136M34.4M395%
EBITDA55.9M-29.28M-191%
Gain YTD28.721129.30422%
P/E Ratio3.427.7844%
Revenue2M0-
Total Cash15.8M15.4M103%
Total Debt860K4.05M21%
FUNDAMENTALS RATINGS
ORMP vs PMN: Fundamental Ratings
ORMP
PMN
OUTLOOK RATING
1..100
8033
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
29100
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
9999
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (1) in the Pharmaceuticals Other industry is significantly better than the same rating for PMN (92) in the null industry. This means that ORMP’s stock grew significantly faster than PMN’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PMN (100) in the null industry. This means that ORMP’s stock grew similarly to PMN’s over the last 12 months.

ORMP's SMR Rating (29) in the Pharmaceuticals Other industry is significantly better than the same rating for PMN (100) in the null industry. This means that ORMP’s stock grew significantly faster than PMN’s over the last 12 months.

PMN's Price Growth Rating (36) in the null industry is in the same range as ORMP (37) in the Pharmaceuticals Other industry. This means that PMN’s stock grew similarly to ORMP’s over the last 12 months.

PMN's P/E Growth Rating (99) in the null industry is in the same range as ORMP (99) in the Pharmaceuticals Other industry. This means that PMN’s stock grew similarly to ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPPMN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 23 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ORMP
Daily Signal:
Gain/Loss:
PMN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLPS1.110.03
+2.78%
CLPS Incorporation
GILD146.232.95
+2.06%
Gilead Sciences
KEX121.510.83
+0.69%
Kirby Corp
NHIC10.40-0.05
-0.48%
Newhold Investment Corp III
EVO3.72-0.07
-1.85%
Evotec SE

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with ACET. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+0.29%
ACET - ORMP
60%
Loosely correlated
-3.51%
ERAS - ORMP
60%
Loosely correlated
+6.19%
GLSI - ORMP
60%
Loosely correlated
-3.62%
PMN - ORMP
59%
Loosely correlated
-1.57%
GPCR - ORMP
59%
Loosely correlated
-3.01%
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been closely correlated with ACET. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if PMN jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-1.57%
ACET - PMN
88%
Closely correlated
-3.51%
ATOS - PMN
87%
Closely correlated
-4.34%
CANF - PMN
87%
Closely correlated
-0.25%
STRO - PMN
87%
Closely correlated
+0.40%
PRAX - PMN
86%
Closely correlated
-2.31%
More